FOXO1 and type 2 diabetes mellitus: Moreover, recent studies from our lab targeting this FoxO1-Pdk4 axis using either AS1842856 (FoxO1 inhibitor) or cardiac-specific FoxO1 elimination alleviated diastolic dysfunction via increasing myocardial glucose oxidation rates in male mice subjected to experimental T2D via HFD supplementation for 10 weeks with a single dose (75 mg/kg) of streptozotocin (STZ) at 4th week [45, 46].